Phase II study of personalized cancer vaccine in CRC shows positive preliminary PFS and long-term ctDNA data

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

The ongoing, signal-seeking phase II portion of the phase II/III study evaluating Granite, a personalized neoantigen cancer vaccine, in front-line metastatic microsatellite stable colorectal cancer, produced positive preliminary data. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Oxaliplatin-based chemotherapy significantly improves survival only in stage 3 colorectal cancer patients aged 70 or younger, according to a study conducted by researchers at Korea University Guro Hospital and Korea University College of Medicine. For patients over 70, the drug offered no survival advantage and led to higher rates of treatment discontinuation due to toxicity. 
A Senate hearing that the administration hoped would be a routine check-in on the president’s 2026 MAHA-driven healthcare agenda erupted into a political firestorm as senators jumped at their first opportunity to confront HHS Secretary Robert F. Kennedy Jr. over the chaos engulfing the Centers for Disease Control and Prevention.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login